Total Payments
$814,882
2024 Payments
$53,268
Companies
35
Transactions
444
Medicare Patients
873
Medicare Billing
$289,181
Payment Breakdown by Category
Consulting$553,764 (68.0%)
Other$166,050 (20.4%)
Travel$59,832 (7.3%)
Research$23,058 (2.8%)
Food & Beverage$11,124 (1.4%)
Education$1,053 (0.1%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $553,764 | 171 | 68.0% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $152,674 | 25 | 18.7% |
| Travel and Lodging | $59,832 | 79 | 7.3% |
| Unspecified | $23,058 | 7 | 2.8% |
| Honoraria | $13,376 | 5 | 1.6% |
| Food and Beverage | $11,124 | 156 | 1.4% |
| Education | $1,053 | 1 | 0.1% |
Payments by Type
General
$791,824
437 transactions
Research
$23,058
7 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | $203,808 | 112 | $0 (2024) |
| Lilly USA, LLC | $129,430 | 36 | $0 (2021) |
| Merck Sharp & Dohme LLC | $100,416 | 61 | $0 (2024) |
| Daiichi Sankyo Inc. | $72,903 | 35 | $0 (2024) |
| Genentech USA, Inc. | $53,389 | 40 | $0 (2024) |
| Celgene Corporation | $38,886 | 24 | $0 (2019) |
| PFIZER INC. | $34,603 | 21 | $0 (2024) |
| Novartis Pharmaceuticals Corporation | $28,797 | 9 | $0 (2024) |
| Takeda Pharmaceuticals U.S.A., Inc. | $23,713 | 9 | $0 (2021) |
| Millennium Pharmaceuticals, Inc. | $19,719 | 7 | $0 (2017) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $53,268 | 41 | Merck Sharp & Dohme LLC ($23,155) |
| 2023 | $113,683 | 77 | Merck Sharp & Dohme LLC ($31,987) |
| 2022 | $77,728 | 43 | AstraZeneca Pharmaceuticals LP ($31,740) |
| 2021 | $84,167 | 32 | Daiichi Sankyo Inc. ($26,091) |
| 2020 | $79,207 | 42 | AstraZeneca Pharmaceuticals LP ($30,297) |
| 2019 | $169,986 | 69 | Lilly USA, LLC ($82,065) |
| 2018 | $93,230 | 68 | AstraZeneca Pharmaceuticals LP ($26,682) |
| 2017 | $143,612 | 72 | AstraZeneca Pharmaceuticals LP ($45,123) |
All Payment Transactions
444 individual payment records from CMS Open Payments — Page 1 of 18
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 11/20/2024 | AstraZeneca Pharmaceuticals LP | TAGRISSO (Drug) | Consulting Fee | Cash or cash equivalent | $3,325.00 | General |
| Category: Oncology | ||||||
| 11/15/2024 | Daiichi Sankyo Inc. | Enhertu (Drug) | Food and Beverage | In-kind items and services | $149.06 | General |
| Category: ONCOLOGY | ||||||
| 11/15/2024 | JAZZ PHARMACEUTICALS INC. | ZEPZELCA (Drug) | Food and Beverage | In-kind items and services | $49.93 | General |
| Category: HEMATOLOGY/ONCOLOGY | ||||||
| 10/29/2024 | Gilead Sciences, Inc. | — | Consulting Fee | Cash or cash equivalent | $3,050.00 | General |
| 10/01/2024 | AstraZeneca Pharmaceuticals LP | IMFINZI (Biological) | Food and Beverage | In-kind items and services | $134.44 | General |
| Category: Oncology | ||||||
| 09/25/2024 | Daiichi Sankyo Inc. | — | Consulting Fee | Cash or cash equivalent | $665.00 | General |
| 09/24/2024 | Janssen Scientific Affairs, LLC | — | Consulting Fee | Cash or cash equivalent | $2,025.00 | General |
| 09/07/2024 | Janssen Scientific Affairs, LLC | — | Food and Beverage | In-kind items and services | $35.00 | General |
| 09/07/2024 | Janssen Scientific Affairs, LLC | — | Food and Beverage | In-kind items and services | $15.00 | General |
| 09/06/2024 | AstraZeneca Pharmaceuticals LP | TAGRISSO (Drug) | Consulting Fee | Cash or cash equivalent | $665.00 | General |
| Category: Oncology | ||||||
| 09/06/2024 | Gilead Sciences, Inc. | Trodelvy (Drug) | Food and Beverage | In-kind items and services | $46.71 | General |
| Category: ONC | ||||||
| 09/06/2024 | Gilead Sciences, Inc. | Trodelvy (Drug) | Food and Beverage | In-kind items and services | $43.58 | General |
| Category: ONC | ||||||
| 09/06/2024 | Gilead Sciences, Inc. | Trodelvy (Drug) | Food and Beverage | In-kind items and services | $25.48 | General |
| Category: ONC | ||||||
| 08/26/2024 | Merck Sharp & Dohme LLC | — | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $4,270.00 | General |
| 08/07/2024 | AstraZeneca Pharmaceuticals LP | — | Food and Beverage | In-kind items and services | $24.58 | General |
| 07/22/2024 | Merck Sharp & Dohme LLC | — | Consulting Fee | Cash or cash equivalent | $7,930.00 | General |
| 07/22/2024 | Merck Sharp & Dohme LLC | — | Travel and Lodging | Cash or cash equivalent | $150.00 | General |
| 07/13/2024 | Merck Sharp & Dohme LLC | KEYTRUDA (Biological) | Food and Beverage | In-kind items and services | $64.99 | General |
| Category: ONCOLOGY | ||||||
| 07/13/2024 | Merck Sharp & Dohme LLC | KEYTRUDA (Biological) | Food and Beverage | In-kind items and services | $55.00 | General |
| Category: ONCOLOGY | ||||||
| 07/13/2024 | Merck Sharp & Dohme LLC | KEYTRUDA (Biological) | Food and Beverage | In-kind items and services | $30.00 | General |
| Category: ONCOLOGY | ||||||
| 07/12/2024 | Merck Sharp & Dohme LLC | KEYTRUDA (Biological) | Travel and Lodging | In-kind items and services | $254.83 | General |
| Category: ONCOLOGY | ||||||
| 07/12/2024 | Merck Sharp & Dohme LLC | KEYTRUDA (Biological) | Food and Beverage | In-kind items and services | $30.00 | General |
| Category: ONCOLOGY | ||||||
| 07/03/2024 | PFIZER INC. | LORBRENA (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $2,250.00 | General |
| Category: ONCOLOGY | ||||||
| 06/28/2024 | Janssen Biotech, Inc. | RYBREVANT (Drug) | Consulting Fee | Cash or cash equivalent | $2,100.00 | General |
| Category: Oncology | ||||||
| 06/21/2024 | Novocure Inc. | Optune Lua (NovoTTF-200T) (Device) | Food and Beverage | Cash or cash equivalent | $158.36 | General |
| Category: Oncology | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| JDQ-PO -116248-Association Between Real-World Upfront Next Generation Sequencing and Overall Survival (OS) in Advanced Non-Small Cell Lung Cancer (aNSCLC) in the United States-ASCO | Novartis Pharmaceuticals Corporation | $9,727 | 1 |
| BI1482694 and pembrolizumab in NSCLC | Boehringer Ingelheim Pharmaceuticals, Inc. | $4,000 | 1 |
| Association Between Real-World Upfront Next Generation Sequencing and OS in aNSCLC in the US-ASCO | Novartis Pharmaceuticals Corporation | $3,565 | 1 |
| CC-486-NSCL-001 - Safety and Efficacy Study of CC-486 With MK-3475 to Treat Locally Advanced or Metastatic Non-small Cell Lung Cancer | Celgene Corporation | $3,444 | 1 |
| CC-486-NSCL-001 | Celgene Corporation | $1,463 | 1 |
| CC-486-NPC-001 - A phase 2, multicenter, international, single arm study to assess the safety and efficacy of single agent cc-486 (oral azacitidine) in previously treated subjects with locally advanced or metastatic n | Celgene Corporation | $442.00 | 1 |
| ABI-007-NSCL-003 | Celgene Corporation | $417.00 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 2 | 165 | 544 | $216,025 | $65,415 |
| 2022 | 2 | 173 | 581 | $189,359 | $72,180 |
| 2021 | 2 | 263 | 686 | $234,624 | $90,303 |
| 2020 | 3 | 272 | 625 | $223,169 | $61,283 |
Total Patients
873
Total Services
2,436
Medicare Billing
$289,181
Procedure Codes
13
All Medicare Procedures & Services
13 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2023 | 113 | 470 | $183,295 | $55,852 | 30.5% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 26 | 48 | $18,225 | $5,522 | 30.3% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Facility | 2023 | 26 | 26 | $14,505 | $4,042 | 27.9% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2022 | 126 | 501 | $161,247 | $61,956 | 38.4% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2022 | 30 | 63 | $20,277 | $7,471 | 36.8% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Facility | 2022 | 17 | 17 | $7,836 | $2,753 | 35.1% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Facility | 2021 | 130 | 508 | $166,242 | $65,383 | 39.3% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Office | 2021 | 66 | 111 | $37,096 | $14,070 | 37.9% |
| 99205 | New patient outpatient visit, total time 60-74 minutes | Facility | 2021 | 67 | 67 | $31,287 | $10,849 | 34.7% |
| 99215 | Established patient office or other outpatient, visit typically 40 minutes | Facility | 2020 | 119 | 380 | $141,856 | $36,671 | 25.9% |
| 99215 | Established patient office or other outpatient, visit typically 40 minutes | Office | 2020 | 63 | 126 | $49,644 | $12,857 | 25.9% |
| 99205 | New patient office or other outpatient visit, typically 60 minutes | Facility | 2020 | 42 | 42 | $21,583 | $6,172 | 28.6% |
| 99443 | Physician telephone patient service, 21-30 minutes of medical discussion | Facility | 2020 | 48 | 77 | $10,087 | $5,582 | 55.3% |
About Dr. Benjamin Levy, MD
Dr. Benjamin Levy, MD is a Hematology & Oncology healthcare provider based in Baltimore, Maryland. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 06/23/2006. The National Provider Identifier (NPI) number assigned to this provider is 1346276326.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Benjamin Levy, MD has received a total of $814,882 in payments from pharmaceutical and medical device companies, with $53,268 received in 2024. These payments were reported across 444 transactions from 35 companies. The most common payment nature is "Consulting Fee" ($553,764).
As a Medicare-enrolled provider, Levy has provided services to 873 Medicare beneficiaries, totaling 2,436 services with total Medicare billing of $289,181. Data is available for 4 years (2020–2023), covering 13 distinct procedure/service records.
Ad
Practice Information
- Specialty Hematology & Oncology
- Other Specialties Hematology & Oncology
- Location Baltimore, MD
- Active Since 06/23/2006
- Last Updated 01/10/2019
- Taxonomy Code 207RH0003X
- Entity Type Individual
- NPI Number 1346276326
Products in Payments
- TAGRISSO (Drug) $153,914
- ALUNBRIG (Drug) $39,953
- CYRAMZA (Drug) $31,552
- Abraxane (Drug) $27,756
- Enhertu (Drug) $26,084
- IMFINZI (Drug) $21,981
- TABRECTA (Drug) $15,506
- LORBRENA (Drug) $15,499
- Alecensa (Biological) $13,892
- Non-Covered Product (Drug) $13,260
- LIBTAYO (Biological) $11,609
- KEYTRUDA (Biological) $10,733
- ENHERTU (Biological) $10,580
- Trodelvy (Drug) $10,000
- IMFINZI (Biological) $8,114
- XALKORI (Drug) $6,551
- Avastin (Biological) $6,320
- RYBREVANT (Drug) $5,991
- TECENTRIQ (Biological) $5,766
- CC-486 (Drug) $5,349
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Hematology & Oncology Doctors in Baltimore
Miss. Ani Balmanoukian, M.d, M.D
Hematology & Oncology — Payments: $842,199
Hematology & Oncology $842,199
Dr. Patrick Forde, M.d, M.D
Hematology & Oncology — Payments: $253,665
Hematology & Oncology $253,665
Josephine Feliciano, M.d, M.D
Hematology & Oncology — Payments: $125,936
Hematology & Oncology $125,936
Djordje Atanackovic, M.d, M.D
Hematology & Oncology — Payments: $117,434
Hematology & Oncology $117,434
Huzefa Bahrain, D.o, D.O
Hematology & Oncology — Payments: $103,816
Hematology & Oncology $103,816
Dr. Maria Baer, Md, MD
Hematology & Oncology — Payments: $99,851
Hematology & Oncology $99,851